Mr. Ahmad Doroudian reports

BETTERLIFE PHARMA ANNOUNCES ISSUANCE OF SHARES AND EXTENSION OF CONVERTIBLE DEBENTURES

Betterlife Pharma Inc. has issued 600,000 common shares to a third party corporate advisor for services rendered beginning October 2025. In addition, the Company has extended maturity dates of convertible debentures issued on February 29, and March 28, 2024. Original maturity dates were February 28, 2026 and March 28, 2026, which have been extended for a further one (1) year term from original maturity.

About Betterlife Pharma Inc.

Betterlife Pharma is an emerging biotechnology company primarily focused on developing and commercializing BETR-001 to treat various neurological disorders. BETR-001, which is in preclinical and IND-enabling (investigational new drug) studies, is a non-hallucinogenic and non-controlled LSD (lysergic acid diethylamide) derivative in development and it is unique in that it is unregulated and therefore can be self-administered. Betterlife's synthesis patent for BETR-001 eliminates regulatory hurdles and its pending patent, for composition and method of use, covers treatment of various neurological disorders, until around 2042.

Betterlife also owns a drug candidate for the treatment of viral infections and is in the process of seeking strategic alternatives for further development.

We seek Safe Harbor.